Evidence map›Paper›PMID 39291152›Full record

ReviewDigital health

Exploring the potential of digital therapeutics: An assessment of progress and promise.

Patrizio Armeni, Irem Polat, Leonardo Maria De Rossi, Lorenzo Diaferia, Severino Meregalli, Anna Gatti

Abstract readReview
In one paragraph

Review in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Trial
  2. Efficacy of guided breathing virtual reality for pain management in patients with cancer undergoing percutaneous transhepatic biliary drainage.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Trial
  3. Neurophysiological Effects of a Digital Therapeutic for Attention-deficit/Hyperactivity Disorder: A Quantitative Electroencephalography Analysis of Theta-Gamma Coupling.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026
    Article
  4. Diving into the Regulatory Landscape of Digital Therapeutics.Therapeutic innovation & regulatory science · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Patrizio ArmeniLIFT Lab, CERGAS GHNP Division, SDA Bocconi School of Management, Milano, Italy.
Irem PolatLIFT Lab, CERGAS GHNP Division, SDA Bocconi School of Management, Milano, Italy.ORCID https://orcid.org/0000-0001-8733-2953
Leonardo Maria De RossiLIFT Lab, CERGAS GHNP Division, and DEVO Lab, Claudio Demattè Research Division, SDA Bocconi School of Management, Milano, Italy.
Lorenzo DiaferiaLIFT Lab, CERGAS GHNP Division, and DEVO Lab, Claudio Demattè Research Division, SDA Bocconi School of Management, Milano, Italy.
Severino MeregalliLIFT Lab, CERGAS GHNP Division, and DEVO Lab, Claudio Demattè Research Division, SDA Bocconi School of Management, Milano, Italy.
Anna GattiLIFT Lab, CERGAS GHNP Division, SDA Bocconi School of Management, Milano, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Digital therapeutics (DTx), a burgeoning subset of digital health solutions, has garnered considerable attention in recent times. These cutting-edge therapeutic interventions employ diverse technologies, powered by software algorithms, to treat, manage, and prevent a wide array of diseases and disorders. Although DTx shows significant promise as an integral component of medical care, its widespread integration is still in the preliminary stages. This limited adoption can be largely attributed to the scarcity of comprehensive research that delves into DTx's scope, including its technological underpinnings, potential application areas, and challenges-namely, regulatory hurdles and modest physician uptake. This review aims to bridge this knowledge gap by offering an in-depth overview of DTx products' value to both patients and clinicians. It evaluates the current state of maturity of DTx applications driven by digital technologies and investigates the obstacles that developers and regulators encounter in the market introduction phase.

Indexed as

artificial intelligencedigital healthdigital medicineDigital therapeuticspolicy and regulationvirtual reality

Identifiers

PMID39291152
PMCPMC11406628

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.